Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
作者： Vincent A. Miller , Mark G. Kris , Neelam Shah , Jyoti Patel , Christopher Azzoli
关键词:
摘要: Purpose Gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, induces radiographic regressions and symptomatic improvement in patients with non–small-cell lung cancer (NSCLC). Phase II trials suggested female sex adenocarcinoma were associated response. We undertook this analysis to identify additional clinical pathologic features sensitivity gefitinib. Patients Methods reviewed medical records, material, imaging studies all 139 NSCLC treated on one three consecutive gefitinib monotherapy performed at our institution. identified experiencing a major objective response compared their others. Univariate multivariable analyses potential predictive Results Of patients, 21 (15%; 95% CI, 9% 21%), experienced partial Variables as signif...
sci-hub.se 参考文章(27)
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
Mark M. Moasser, Steven D. Averbuch, Neal Rosen, Andrea Basso, The Tyrosine Kinase Inhibitor ZD1839 ("Iressa") Inhibits HER2-driven Signaling and Suppresses the Growth of HER2-overexpressing Tumor Cells Cancer Research. ,vol. 61, pp. 7184- 7188 ,(2001)
J P O'Connell, M G Kris, R J Gralla, S Groshen, A Trust, J J Fiore, D P Kelsen, R T Heelan, R B Golbey, Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. Journal of Clinical Oncology. ,vol. 4, pp. 1604- 1614 ,(1986) , 10.1200/JCO.1986.4.11.1604
Frank V. Fossella, Russell DeVore, Ronald N. Kerr, Jeffrey Crawford, Ronald R. Natale, Frank Dunphy, Leonard Kalman, Vincent Miller, Jin Soo Lee, Melvin Moore, David Gandara, Daniel Karp, Everett Vokes, Mark Kris, Yong Kim, Francis Gamza, Luz Hammershaimb, , Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Journal of Clinical Oncology. ,vol. 18, pp. 2354- 2362 ,(2000) , 10.1200/JCO.2000.18.12.2354
Carlos L. Arteaga, The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. Journal of Clinical Oncology. ,vol. 19, ,(2001)
Steven A. Ahrendt, P. Anthony Decker, Enas A. Alawi, Yong-ran Zhu, Montserrat Sanchez-Cespedes, Stephen C. Yang, George B. Haasler, André Kajdacsy-Balla, Michael J. Demeure, David Sidransky, Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. ,vol. 92, pp. 1525- 1530 ,(2001) , 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H
G DEMETRI, Targeting c-kit mutations in solid tumors: Scientific rationale and novel therapeutic options Seminars in Oncology. ,vol. 28, pp. 19- 26 ,(2001) , 10.1016/S0093-7754(01)90099-5
Stephanie Green, Geoffrey R. Weiss, Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Investigational New Drugs. ,vol. 10, pp. 239- 253 ,(1992) , 10.1007/BF00944177
Maria P. Wong, Lai-Fan Fung, Elaine Wang, Wing-Shun Chow, Shui-Wah Chiu, Wah-Kit Lam, Kwok-Keung Ho, Edmond S. K. Ma, Thomas S. K. Wan, Lap-Ping Chung, Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. Cancer. ,vol. 97, pp. 1263- 1270 ,(2003) , 10.1002/CNCR.11183
Gary A Giovino, Epidemiology of tobacco use in the United States Oncogene. ,vol. 21, pp. 7326- 7340 ,(2002) , 10.1038/SJ.ONC.1205808